CEL-SCI’s Multikine Immunotherapy Boosts 5-Year Survival Rate in Head and Neck Cancer CEL-SCI Corporation (NYSE American: CVM) has announced new breakthrough data from its Phase… BioTech Health XSeptember 16, 2024 0 Shares 0 0 0 0 0 0 0
Novartis Pioneers RNA Therapeutics with Borealis Biosciences for Kidney Diseases BioTech Health XAugust 22, 2024
Genentech’s Strategic Pivot: The Closure of Its Cancer Immunology Unit BioTech Health XAugust 22, 2024
Breakthrough in Alzheimer’s Treatment: Biogen and Eisai’s Leqembi Wins UK Approval BioTech Health XAugust 22, 2024
Vera Therapeutics’ Atacicept Shows Promising Results in Phase 2b ORIGIN Trial for IgA Nephropathy BioTech Health XMay 25, 2024
Biotech NewsCEL-SCI’s Multikine Immunotherapy Boosts 5-Year Survival Rate in Head and Neck Cancer BioTech Health XSeptember 16, 2024
Biotech NewsNovartis Pioneers RNA Therapeutics with Borealis Biosciences for Kidney Diseases BioTech Health XAugust 22, 2024
Biotech NewsGenentech’s Strategic Pivot: The Closure of Its Cancer Immunology Unit BioTech Health XAugust 22, 2024
Biotech NewsBreakthrough in Alzheimer’s Treatment: Biogen and Eisai’s Leqembi Wins UK Approval BioTech Health XAugust 22, 2024
Biotech NewsVera Therapeutics’ Atacicept Shows Promising Results in Phase 2b ORIGIN Trial for IgA Nephropathy BioTech Health XMay 25, 2024
CEL-SCI’s Multikine Immunotherapy Boosts 5-Year Survival Rate in Head and Neck Cancer BioTech Health XSeptember 16, 2024 CEL-SCI Corporation (NYSE American: CVM) has announced new breakthrough data from its Phase 3 trial of Multikine®, an… Read More 0 Shares 0 0 0 0 0 0 0
Novartis Pioneers RNA Therapeutics with Borealis Biosciences for Kidney Diseases BioTech Health XAugust 22, 2024 Introduction In a groundbreaking move for the biotech industry, Novartis has partnered with Versant Ventures to establish Borealis… Read More 0 Shares 0 0 0 0 0 0 0
Genentech’s Strategic Pivot: The Closure of Its Cancer Immunology Unit BioTech Health XAugust 22, 2024 Introduction In a significant and somewhat unexpected move within the biotech industry, Genentech, a subsidiary of Roche, has… Read More 0 Shares 0 0 0 0 0 0 0
Breakthrough in Alzheimer’s Treatment: Biogen and Eisai’s Leqembi Wins UK Approval BioTech Health XAugust 22, 2024 Introduction The landscape of Alzheimer’s disease treatment has undergone a monumental shift with the UK’s Medicines and Healthcare… Read More 0 Shares 0 0 0 0 0 0 0
Vera Therapeutics’ Atacicept Shows Promising Results in Phase 2b ORIGIN Trial for IgA Nephropathy BioTech Health XMay 25, 2024 Vera Therapeutics has announced positive results from their Phase 2b ORIGIN clinical trial for atacicept, a novel investigational… Read More 0 Shares 0 0 0 0 0 0 0
Ozempic Shows Lower Risk of Kidney and Heart Complications in Diabetic Patients BioTech Health XMay 24, 2024 In a groundbreaking development, Novo Nordisk’s Ozempic (semaglutide) has demonstrated significant benefits in reducing the risk of kidney… Read More 0 Shares 0 0 0 0 0 0 0
Eli Lilly Announces Historic $5.3 Billion Investment to Expand Indiana Manufacturing for Diabetes and Weight Loss Drugs BioTech Health XMay 24, 2024 Expansion to Create 900 Permanent Jobs and Meet Rising Demand for Mounjaro and Zepbound Eli Lilly and Company… Read More 0 Shares 0 0 0 0 0 0 0
Guardant Health’s Shield Blood Test for Colorectal Cancer Receives FDA Advisory Panel Endorsement BioTech Health XMay 24, 2024 Guardant Health, a prominent player in precision oncology, has taken a significant step forward with its Shield blood… Read More 0 Shares 0 0 0 0 0 0 0
Coherus Presents Promising Phase I Results for Anti-CCR8 Antibody CHS-114 at ASCO 2024 BioTech Health XMay 23, 2024 Coherus BioSciences has announced preliminary results from its Phase I dose-escalation study of CHS-114, an anti-CCR8 antibody, at… Read More 0 Shares 0 0 0 0 0 0 0
Myriad Genetics Unveils Groundbreaking Cancer Care Innovations at ASCO 2024 BioTech Health XMay 23, 2024 Myriad Genetics has once again solidified its position at the forefront of precision medicine and genetic testing with… Read More 0 Shares 0 0 0 0 0 0 0
Biogen Expands Immunology Portfolio with Strategic Acquisition BioTech Health XMay 23, 2024 Biogen Inc. has announced the acquisition of Human Immunology Biosciences (HI-Bio) for an upfront payment of $1.15 billion,… Read More 0 Shares 0 0 0 0 0 0 0
Takeda Inks Licensing Deal with Degron Therapeutics for Molecular Glue Degraders BioTech Health XMay 23, 2024 Takeda Pharmaceuticals has announced an exclusive licensing agreement with Degron Therapeutics, a Chinese biotech company, to develop novel… Read More 0 Shares 0 0 0 0 0 0 0
FDA Approves Biosimilars Yesafili and Opuviz, Opening New Avenues for Affordable Eye Treatments BioTech Health XMay 21, 2024 The FDA has recently approved two new biosimilars, Yesafili (aflibercept-jbvf) by Biocon Biologics and Opuviz (aflibercept-yszy) by Samsung… Read More 0 Shares 0 0 0 0 0 0 0
Oak Hill Bio and Chiesi Resume Phase 2b Clinical Study for OHB-607 to Treat Bronchopulmonary Dysplasia BioTech Health XMay 17, 2024 Oak Hill Bio and Chiesi Group have announced the enrollment of the first patient in a resumed Phase… Read More 0 Shares 0 0 0 0 0 0 0
FDA Delays Moderna RSV Vaccine Decision BioTech Health XMay 13, 2024 Moderna’s RSV vaccine, mRNA-1345, has experienced a delay in FDA approval, initially expected by May 12 but now… Read More 0 Shares 0 0 0 0 0 0 0
Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships BioTech Health XMay 10, 2024 Novavax (NASDAQ: NVAX), a leader in vaccine innovation, today reported substantial progress in its financial and operational goals… Read More 0 Shares 0 0 0 0 0 0 0
Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts BioTech Health XMay 10, 2024 In a landmark agreement, Novavax (NASDAQ: NVAX) has partnered with French pharmaceutical giant Sanofi to escalate the fight… Read More 0 Shares 0 0 0 0 0 0 0
CEL-SCI Advances in Cancer Treatment with FDA Approval for Confirmatory Multikine Study BioTech Health XMay 8, 2024 In a landmark decision, the U.S. Food and Drug Administration (FDA) has green-lighted CEL-SCI Corporation (NYSE American: CVM)… Read More 0 Shares 0 0 0 0 0 0 0